Clinical Report: The Role of Pelvic Radiotherapy in High-Risk Localized Prostate Cancer
Overview
This report examines the role of elective pelvic radiotherapy (WPRT) in high-risk localized prostate cancer, highlighting the importance of patient selection based on nodal risk and systemic therapy integration. Recent trials suggest that while WPRT may offer benefits in specific populations, it is not universally applicable due to associated toxicity and variable outcomes.
Background
The management of high-risk localized prostate cancer has evolved significantly, with advances in radiotherapy and systemic therapies. The debate surrounding elective pelvic radiotherapy has been contentious, with concerns about its toxicity and limited incremental benefits. Understanding which patients may benefit from WPRT is crucial for optimizing treatment outcomes.
Data Highlights
No specific numerical data presented in the article.
Key Findings
Systemic intensification with androgen deprivation therapy (ADT) significantly improves metastasis-free survival (MFS) and overall survival (OS) in high-risk prostate cancer.
WPRT does not demonstrate a global benefit in event-free survival or OS compared to prostate-only RT in broader-risk cohorts.
Carefully selected patients with a high probability of nodal involvement may benefit from WPRT, as shown in the POP-RT trial.
Higher rates of gastrointestinal toxicity are associated with WPRT, necessitating careful patient selection and advanced delivery techniques.
Contemporary analyses support a selective approach to WPRT, particularly in patients with high nodal risk.
Clinical Implications
Clinicians should consider the individual patient's nodal risk and the potential benefits of systemic therapy when deciding on the use of WPRT. Advanced radiotherapy techniques are essential to minimize toxicity while maximizing therapeutic benefits in selected high-risk patients.
Conclusion
The role of WPRT in high-risk localized prostate cancer should be approached with caution, focusing on patient selection and integration with systemic therapies to optimize outcomes.
